A practical guide to the handling and administration of talimogene laherparepvec in Europe. 2017

Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
NIHR Biomedical Research Centre, The Institute of Cancer Research/The Royal Marsden Hospital, London, UK.

Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection. This review provides a practical overview of handling, storage, and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be transported/stored frozen at a temperature of -90°C to -70°C, and once thawed, vials must not be refrozen. Universal precautions for preparation, administration, and handling should be followed to avoid accidental exposure. Health care providers should wear personal protective equipment, and materials that come into contact with talimogene laherparepvec should be disposed of in accordance with local institutional procedures. Individuals who are immunocompromised or pregnant should not prepare or administer this agent. Talimogene laherparepvec is administered by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, palpable, or detectable by ultrasound. Treatment should be continued for ≥6 months. As with other immunotherapies, patients may experience an increase in the size of existing lesion(s) or the appearance of new lesions (ie, progression) prior to achieving a response ("pseudo-progression"). As several health care professionals (eg, physicians [dermatologists, surgeons, oncologists, radiologists], pharmacists, nurses) are involved in different stages of the process, there is a need for good interdisciplinary collaboration when using talimogene laherparepvec. Although there are specific requirements for this agent's storage, handling, administration, and disposal, these can be effectively managed in a real-world clinical setting through the implementation of training programs and straightforward standard operating procedures.

UI MeSH Term Description Entries

Related Publications

Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
December 2018, European journal of dermatology : EJD,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
March 2016, Oncology nursing forum,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
April 2022, JAMA dermatology,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
July 2018, Annals of surgical oncology,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
January 2015, Expert opinion on biological therapy,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
November 2020, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.],
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
November 2021, The Journal of clinical and aesthetic dermatology,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
November 2015, Melanoma management,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
October 2016, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Kevin J Harrington, and Olivier Michielin, and Josep Malvehy, and Isabella Pezzani Grüter, and Lorna Grove, and Anna Lisa Frauchiger, and Reinhard Dummer
April 2020, Transplantation,
Copied contents to your clipboard!